ClinicalTrialsFinder

KRAS G12C-mutated Solid Tumors, Lung Cancer Clinical Trials in New York, New York

1 recruitingNew York, New York

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Non-small Cell Lung Cancer (NSCLC)KRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc.616 enrolled89 locationsNCT06162221